# US 2026/0229351 A1 · Integrated AI-driven System for Early Detection of Cervical and Breast Cancer Using Multi-Modal Imaging, Liquid Biopsy, and Epigenetic Biomarkers.

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0229351 A1
- Document ID: US20260229351A1
- Status: Published application
- Kind: A1
- Application number: 19/067,907
- Filed: 2025-03-02
- Published: 2026-08-06
- Earliest claimed: 2025-03-02
- Inventors: FURONG BEI
- Web page: https://patentgrep.com/patent/US20260229351A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- B01L 3/5027: {by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip}
- G01N 21/6486: {Measuring fluorescence of biological material, e.g. DNA, RNA, cells (G01N21/6428 takes precedence)}
- G16H 30/20: for handling medical images, e.g. DICOM, HL7 or PACS
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A quantum-dot-enhanced CRISPR-Cas13a microfluidic molecular triage and clinical routing system for rapid high-risk human papillomavirus genotyping in cervical and breast cancer care pathways includes a disposable microfluidic cartridge and a reader for rapid genotyping of high-risk human papillomavirus from cervical samples. The cartridge includes a sample inlet, lysis zone, CRISPR reaction zone, optical detection zone, and waste reservoir. At least one reaction microchannel has a width of about 100 micrometers and a depth of about 50 micrometers. A CRISPR-Cas13a assay is incubated at about 37 degrees Celsius for about 15 minutes. Fluorescence from a quantum-dot reporter having a peak emission at about 605 nanometers is detected to generate a same-visit triage output indicating HPV16/18 positive, other high-risk HPV positive, negative, invalid, or repeat-test recommended. Optional communications features support secure transmission of results or run metadata to patient, provider, emergency, or reimbursement interfaces.

## Claims

### Claim 1

A quantum-dot-enhanced CRISPR-Cas13a microfluidic molecular triage system for rapid genotyping of high-risk human papillomavirus (HPV) from a cervical sample, comprising: disposable microfluidic cartridge comprising a sample inlet, a lysis zone, a CRISPR reaction zone, an optical detection zone, and a waste reservoir; and a reader configured to receive the cartridge and comprising a heater, an optical excitation-and-detection assembly, and a processor; wherein the CRISPR reaction zone includes at least one reaction microchannel having a width of about 100 micrometers and a depth of about 50 micrometers; wherein the system is configured to incubate a CRISPR-Cas13a assay at about 37 degrees Celsius for about 15 minutes; and wherein the optical detection zone is configured to detect fluorescence from a quantum-dot reporter having a peak emission at about 605 nanometers and the processor is configured to generate a same-visit triage result indicating at least one of HPV16/18 positive, other high-risk HPV positive, negative, invalid, or repeat-test recommended.

### Claim 2 (depends on 1)

The system of claim 1, wherein the cartridge comprises separate reaction regions corresponding to HPV16, HPV18, pooled high-risk HPV, and an internal control.

### Claim 3 (depends on 1)

The system of claim 1, wherein the cartridge is single-use and sealed after sample loading.

### Claim 4 (depends on 1)

The system of claim 1, wherein the cartridge comprises a polymeric substrate selected from cyclic olefin copolymer, cyclic olefin polymer, polycarbonate, and polymethyl methacrylate.

### Claim 5 (depends on 1)

The system of claim 1, wherein the heater is configured to maintain the CRISPR reaction within a tolerance band around 37 degrees Celsius during the incubation.

### Claim 6 (depends on 1)

The system of claim 1, wherein the processor suppresses issuance of a positive or negative result and outputs invalid or repeat-test recommended when an internal control fails a predetermined acceptance criterion.

### Claim 7 (depends on 1)

The system of claim 1, wherein the optical excitation-and-detection assembly comprises at least one light source, at least one optical filter, and at least one photodetector aligned with a cartridge read window.

### Claim 8 (depends on 1)

the system of claim 1, further comprising a communications interface configured to transmit the triage result or associated run metadata to a patient portal, provider portal, clinical coordination endpoint, pricing interface, reimbursement interface, or combinations thereof.

### Claim 9 (depends on 1)

The system of claim 1, wherein the reader or a communicatively coupled device displays the triage result together with a same-visit routing instruction, follow-up recommendation, or workflow status indicator.

### Claim 10

A method for rapid high-risk HPV genotyping and same-visit triage using a cervical sample, comprising: introducing the cervical sample into a disposable microfluidic cartridge comprising a sample inlet, a lysis zone, a CRISPR reaction zone, an optical detection zone, and a waste reservoir; lysing the cervical sample on-chip or in a chamber fluidically coupled to the cartridge; transporting lysed sample into at least one reaction microchannel having a width of about 100 micrometers and a depth of about 50 micrometers; incubating a CRISPR-Cas13a reaction in the cartridge at about 37 degrees Celsius for about 15 minutes; optically detecting fluorescence from a quantum-dot reporter having a peak emission at about 605 nanometers; and generating, with a processor, a same-visit triage result indicating at least one of HPV16/18 positive, other high-risk HPV positive, negative, invalid, or repeat-test recommended.

### Claim 11 (depends on 10)

The method of claim 10, further comprising verifying an internal control before issuing the triage result.

### Claim 12 (depends on 10)

The method of claim 10, wherein the optical detection comprises interrogating separate reaction regions corresponding to HPV16, HPV18, pooled high-risk HPV, and an internal control.

### Claim 13 (depends on 10)

The method of claim 10, further comprising generating invalid or repeat-test recommended output when the internal control fails a predetermined acceptance criterion or when signal-to-noise criteria are not satisfied.

### Claim 14 (depends on 10)

The method of claim 10, further comprising storing or exporting a run log associated with assay version, cartridge lot, and result category.

### Claim 15 (depends on 10)

The method of claim 10, further comprising transmitting the triage result or associated run metadata to a remote endpoint associated with patient-facing review, provider-facing review, emergency coordination, pricing handling, reimbursement handling, or combinations thereof, and presenting a same-visit routing instruction based on the triage result.

### Claim 16

A kit for quantum-dot-enhanced CRISPR-Cas13a microfluidic molecular triage of a cervical sample, comprising: a disposable microfluidic cartridge comprising a sample inlet, a lysis zone, a CRISPR reaction zone, an optical detection zone, and a waste reservoir, wherein the CRISPR reaction zone includes at least one reaction microchannel having a width of about 100 micrometers and a depth of about 50 micrometers; CRISPR-Cas13a reagents configured for incubation at about 37 degrees Celsius for about 15 minutes; at least one quantum-dot reporter having a peak emission at about 605 nanometers; and instructions for use with a reader configured to generate a same-visit triage result.

### Claim 17 (depends on 16)

The kit of claim 16, further comprising an internal control reagent or control region corresponding to run-validity checking.

### Claim 18 (depends on 16)

The kit of claim 16, further comprising a positive control, a negative control, cervical swabs, and lysis buffer containers.

### Claim 19 (depends on 16)

The kit of claim 16, wherein the kit is packaged for same-visit cervical screening in an outpatient clinic, community screening site, mobile program, pharmacy, physician office, or combinations thereof.

### Claim 20 (depends on 16)

The kit of claim 16, wherein the instructions describe transmission of triage results to a patient portal, provider portal, emergency coordination interface, pricing interface, reimbursement interface, or combinations thereof, and operation as a first-access molecular triage node within a broader clinical routing architecture.
